LianBio: Pfizer Opts In to Commercialize RSV Candidate Sisunatovir in Greater China, Singapore
2022年12月19日 - 09:48PM
Dow Jones News
By Chris Wack
LianBio said Monday that Pfizer Inc. opted in to the right to
develop and commercialize sisunatovir, a drug candidate to treat
respiratory syncytial virus, in mainland China, Hong Kong, Macau
and Singapore as part of the companies' collaboration.
Under the terms of Pfizer's opt-in, LianBio will receive a $20
million upfront payment.
Sisunatovir is an investigational, orally administered fusion
inhibitor designed to block RSV replication by inhibiting
F-mediated fusion with the host cell. Sisunatovir is being
evaluated for the potential treatment of RSV infection in pediatric
and adult patients.
In June, Pfizer acquired ReViral Ltd. and its portfolio of RSV
therapeutic candidates with the exception of development and
commercialization rights for sisunatovir in greater China and
Singapore, which LianBio had previously in-licensed from ReViral in
March 2021.
LianBio is eligible to receive up to $135 million in potential
development and commercial milestone payments and tiered low
single-digit percent of sisunatovir net sales in the territories.
Pfizer will assume all development and commercial activities and
costs in the region and will release LianBio from its royalty and
milestone obligations for sisunatovir.
LianBio ADRs were up 11% to $1.50 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 19, 2022 07:33 ET (12:33 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 2 2024 まで 3 2024
Pfizer (NYSE:PFE)
過去 株価チャート
から 3 2023 まで 3 2024